1. bookVolume 28 (2015): Issue 1 (March 2015)
Journal Details
License
Format
Journal
eISSN
2300-6676
ISSN
2084-980X
First Published
30 May 2014
Publication timeframe
4 times per year
Languages
English
access type Open Access

The activity of micafungin against clinical isolates of non-albicans Candida spp.

Published Online: 09 May 2015
Volume & Issue: Volume 28 (2015) - Issue 1 (March 2015)
Page range: 13 - 16
Received: 02 Mar 2015
Accepted: 12 Mar 2015
Journal Details
License
Format
Journal
eISSN
2300-6676
ISSN
2084-980X
First Published
30 May 2014
Publication timeframe
4 times per year
Languages
English
Abstract

Infections caused by non-albicans Candida spp. are an important medical problem in people from risk groups, e.g. hematooncological patients. The aim of this paper was to analyse the in vitro activity of micafungin against 30 clinical isolates of non-albicans Candida spp. (C. glabrata, C. famata, C. tropicalis, C. inconspicua, C. lusitaniae, C. parapsilosis, C. krusei) by way of the E-test procedure, allowing determination of minimal inhibitory concentration (MIC). Data presented in this paper indicate that most of the studied clinical isolates - 27 (90%) showed sensitivity to micafungin, with MIC values ranging from 0.004 to 2 mg/l, while 3 (10%) isolates, including 2 isolates of C. tropicalis and 1 isolate of C. famata, were resistant to micafungin, with MIC values > 32 mg/l. The MIC50 and MIC90 values of micafungin, defined as MIC inhibited growth of 50% or 90% of the isolates studied, were 0.008 mg/l or 2 mg/l, respectively. In the case of C. glabrata isolates, MICs ranged from 0.004 to 0.016 mg/l, while MIC50 was 0.004 mg/l and MIC90 - 0.008 mg/l. Our data confirm the utility of micafungin for the therapy of the infections caused by non-albicans Candida spp., especially C. glabrata.

Keywords

1. Abuhammour W., Habte-Gaber E.: Newer antifungal agents. Indian. J. Pediatr., 71, 253, 2004.Search in Google Scholar

2. Andes D.R. et al.: In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother., 52, 3497, 2008.10.1128/AAC.00478-08256591618625768Search in Google Scholar

3. Arendrup M.C. et al.: European Committee for Antimicrobial Susceptibility Testing (EUCAST). Methods for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. EUCAST definitive document EDef 7.2 Revision. March 2012.10.1111/j.1469-0691.2012.03880.x22563750Search in Google Scholar

4. Baran E., Dyląg M.: Echinokandyny - wielkocząsteczkowe lipopeptydy o aktywności przeciwgrzybiczej. Przegl. Dermatol., 93, 131, 2006.Search in Google Scholar

5. Barry A.L. et al.: Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol., 38, 3457, 2000.10.1128/JCM.38.9.3457-3459.20008740610970403Search in Google Scholar

6. Bennett J.E., Izumikawa K., Marr K.A.: Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother., 48, 1773, 2004.Search in Google Scholar

7. Bormann A.M., Morrison V.A.: Review of the pharmacology and clinical studies of micafungin. Drug Des. Devel. Ther., 29, 295, 2009.Search in Google Scholar

8. Carter N.J., Keating G.M.: Micafungin: A review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients. Paediatr Drugs., 11, 271, 2009.Search in Google Scholar

9. Chandrasekar P.H., Sobel J.D.: Micafungin: A new echinocandin. Clin. Infect. Dis., 42, 1171, 2006.Search in Google Scholar

10. Chion Ch., Groll A., Walsh T.: New drugs and novel targets for treatment of invasive fungal infections. Oncologist., 2, 120, 2000.Search in Google Scholar

11. Choi H.W. et al.: In vitro susceptibilities to caspofungin and micafungin of clinical isolates of Candida species. Korean J. Lab. Med., 26, 275, 2006.10.3343/kjlm.2006.26.4.27518156738Search in Google Scholar

12. Dzierżanowska D.: Nowe antybiotyki stosowane w terapii inwazyjnych zakażeń grzybiczych. Zakażenia, 8, 34, 2008.Search in Google Scholar

13. Dzierżanowska D. (2007). Patogeny zakażeń szpitalnych. Bielsko- Biała: α-medicapress.Search in Google Scholar

14. Dzierżanowska D. (2007). Postacie kliniczne zakażeń szpitalnych. Bielsko-Biała: α-medicapress.Search in Google Scholar

15. Eschenauer G., de Pestel D.D., Carver P.L.: Comparison of echinocandin antifungals. Ther. Clin. Risk. Manag., 3, 71, 2007.Search in Google Scholar

16. Hashimoto S.: Micafungin: A sulfated echinocandin. J. Antibiot., 62, 27, 2009.10.1038/ja.2008.319132058Search in Google Scholar

17. Ikeda F. et al.: Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med. Mycol., 47, 145, 2009.10.1080/1369378080226212318668422Search in Google Scholar

18. Joseph J.M., Jain R., Danziger L.H.: Micafungin: A new echinocandin antifungal. Pharmacother., 27, 53, 2007.Search in Google Scholar

19. Karthaus M., Cornely O.A.: Treatment options in candidaemia. Mycoses, 50, 44, 2007.Search in Google Scholar

20. Messer S.A. et al.: Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol., 44, 324, 2006.10.1128/JCM.44.2.324-326.2006139270216455878Search in Google Scholar

21. Morris M.I., Villmann M.: Echinocandins in the management of invasive fungal infections. Am. J. Health-Syst. Pharm., 63, 1693, 2006.Search in Google Scholar

22. Nakai T. et al: In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelia forms. Antimicrob. Agents Chemother., 47, 1376, 2003.10.1128/AAC.47.4.1376-1381.200315253212654673Search in Google Scholar

23. Nguyen K.T. et al.: Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates. Int. J. Antimicrob. Agents., 35, 80, 2010.10.1016/j.ijantimicag.2009.09.00319889519Search in Google Scholar

24. Oliveira E.R. et al.: Antifungal susceptibility testing of micafungin against Candida glabrata isolates. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 105, 457, 2008.10.1016/j.tripleo.2007.12.00318329581Search in Google Scholar

25. Pappas P.G. et al.: Micafungin versus caspofungin for treatment of candidaemia and other forms of invasive candidiasis. Clin. Infect. Dis., 45, 883, 2007.Search in Google Scholar

26. Pfaller M.A. et al.: Wild-type MIC distributions and epidemiological cut off values for the echinocandins and Candida spp. J. Clin. Microbiol., 48, 52, 2010.10.1128/JCM.01590-09281227119923478Search in Google Scholar

27. Pfaller M.A. et al.: In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin and micafungin: Six years of global surveillance. J. Clin. Microbiol., 46, 150, 2008.Search in Google Scholar

28. Pfaller M.A. et al.: Global surveillance of in vitro activity of micafungin against Candida: A comparison with caspofungin by CLSI - recommended methods. J. Clin. Microbiol., 44, 3533, 2006.10.1128/JCM.00872-06159480217021079Search in Google Scholar

29. Pfaller M.A. et al.: Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol., 46, 2620, 2008.10.1128/JCM.00566-08251950318579718Search in Google Scholar

30. Pfeiffer C.D. et al.: Breakthrough invasive candidiasis on micafungin. J. Clin. Microbiol., 48, 2373, 2010.10.1128/JCM.02390-09289749320421445Search in Google Scholar

31. Prasad R., Kappor K.: Multidrug resistance in yeasts Candida. Int. Rev. Cytol., 242, 215, 2005.Search in Google Scholar

32. Quindos G. et al.: In vitro antifungal activity of micafungin. Rev. Iberoam. Micol., 26, 35, 2009.Search in Google Scholar

33. Quindos G., Villar-Vidal M., Eraso E.: Activity of micafungin against Candida biofilms. Rev. Iberoam. Micol., 26, 49, 2009.Search in Google Scholar

34. Resende M.A. et al.: Prevalence and antifungal susceptibility of yeasts obtained from the oral cavity of elderly individuals. Mycopathologia, 162, 39, 2006.10.1007/s11046-006-0029-616830190Search in Google Scholar

35. Sucher A.J., Chahine E.B., Balcer H.E.: Echinocandins: The newest class of antifungals. Ann. Pharmacother., 43, 1647, 2009.Search in Google Scholar

36. Temesgen Z., Barreto J., Vento S.: Micafungin - the newest echinocandin. Drugs Today, 45, 469, 2009.Search in Google Scholar

37. Turner M.S., Drew R.H., Perfect J.R.: Emerging echinocandins for treatment of invasive fungal infections. Expert Opin. Emerg. Drugs., 11, 231, 2006.Search in Google Scholar

38. White T.C. et al.: Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother., 46, 1704, 2002. 10.1128/AAC.46.6.1704-1713.200212724512019079Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo